 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
8 News |  |
- || CD19-targeted CAR-T cells / Sinobioway
Enrollment closed, Enrollment change, Trial completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Jul 15, 2020
P=N/A, N=72, Active, not recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Recruiting --> Active, not recruiting | N=24 --> 72 | Trial completion date: Nov 2019 --> Dec 2025
- CD19-targeted CAR-T cells / Sinobioway
New trial, CAR T-Cell Therapy: CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma (clinicaltrials.gov) - Apr 3, 2018
P=N/A, N=6, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- CD19-targeted CAR-T cells / Sinobioway
Enrollment open: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Recruiting --> Active, not recruiting | N=24 --> 72 | Trial completion date: Nov 2019 --> Dec 2025 Suspended --> Recruiting
- CD19-targeted CAR-T cells / Sinobioway
Phase classification, Trial primary completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Suspended --> Recruiting Phase classification: P1/2 --> P=N/A | Trial primary completion date: May 2019 --> Nov 2019
- CD19-targeted CAR-T cells / Sinobioway
Phase classification, Trial initiation date, Trial suspension, Trial primary completion date: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=24, Suspended, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Trial primary completion date: May 2019 --> Nov 2019 Phase classification: P1/2 --> P=N/A | Initiation date: Nov 2015 --> Jul 2015 | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2019
- CD19-targeted CAR-T cells / Sinobioway
Trial primary completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Nov 22, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Initiation date: Nov 2015 --> Jul 2015 | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2019 Trial primary completion date: Oct 2016 --> May 2019
- CD19-targeted CAR-T cells / Sinobioway
New P1/2 trial: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Apr 12, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- CD19-targeted CAR-T cells / Sinobioway
New P1/2 trial: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.